Payment overview · 2025
General Payments
$441.22
21 reported records · 8 companies
Healthcare provider profile · identity verified
Steven O. Stewart, MD
Allopathic & Osteopathic Physicians|Family Medicine · TUCKER, GA · NPI 1679579643
Verified facts
What the public records show
CMS Open Payments records show Steven O. Stewart, MD received $441.22 in general payments during 2025 across 21 reported records.
Novo Nordisk Inc accounted for 40.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Ozempic.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 103 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $177.64 | 40.3% | 8 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $128.91 | 29.2% | 6 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $31.67 | 7.2% | 2 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $25.96 | 5.9% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $24.83 | 5.6% | 1 | 2025 |
| BIOTRONIK NRO, Inc. | Unresolved — no canonical attribution shown | $23.87 | 5.4% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.64 | 3.3% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $13.70 | 3.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $441.22 | 21 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $104.82 | 7 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $104.82 | 7 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $103.96 | 5 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $103.96 | 5 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $72.82 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $31.67 | 2 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $25.96 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $24.95 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $24.83 | 1 | 2025 |
Source payment records
|
|||||
| Prospera Normalized: prospera |
Device | BIOTRONIK NRO, Inc. | $23.87 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $14.64 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $13.70 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 46 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 103 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
46 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
103 | 20 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 484 | 148 |
| Atorvastatin Calcium | Atorvastatin Calcium | 451 | 148 |
| Levothyroxine Sodium | Levothyroxine Sodium | 286 | 82 |
| Metoprolol Succinate | Metoprolol Succinate | 221 | 66 |
| Metformin Hcl | Metformin Hcl | 205 | 60 |
| Losartan Potassium | Losartan Potassium | 194 | 63 |
| Gabapentin | Gabapentin | 183 | 53 |
| Glimepiride | Glimepiride | 133 | 41 |
| Trazodone Hcl | Trazodone Hcl | 127 | 34 |
| Hydrochlorothiazide | Hydrochlorothiazide | 121 | 41 |
| Pravastatin Sodium | Pravastatin Sodium | 119 | 32 |
| Simvastatin | Simvastatin | 118 | 37 |
| Lisinopril | Lisinopril | 114 | 36 |
| Pantoprazole Sodium | Pantoprazole Sodium | 112 | 34 |
| Azithromycin | Azithromycin | 110 | 81 |
| Ozempic | Semaglutide | 103 | 20 |
| Furosemide | Furosemide | 100 | 33 |
| Metformin Hcl Er | Metformin Hcl | 99 | 33 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 98 | 55 |
| Allopurinol | Allopurinol | 97 | 30 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 97 | 36 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 96 | 31 |
| Nifedipine Er | Nifedipine | 93 | 28 |
| Meloxicam | Meloxicam | 88 | 35 |
| Eliquis | Apixaban | 86 | 18 |
| Methylprednisolone | Methylprednisolone | 79 | 57 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 76 | 24 |
| Tamsulosin Hcl | Tamsulosin Hcl | 76 | 21 |
| Potassium Chloride | Potassium Chloride | 75 | 26 |
| Carvedilol | Carvedilol | 69 | 23 |
| Omeprazole | Omeprazole | 69 | 23 |
| Fluticasone Propionate | Fluticasone Propionate | 65 | 30 |
| Ezetimibe | Ezetimibe | 62 | 18 |
| Metoprolol Tartrate | Metoprolol Tartrate | 60 | 19 |
| Montelukast Sodium | Montelukast Sodium | 55 | 19 |
| Hydralazine Hcl | Hydralazine Hcl | 54 | 18 |
| Quetiapine Fumarate | Quetiapine Fumarate | 51 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 50 | 17 |
| Ibuprofen | Ibuprofen | 50 | 20 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 49 | 23 |
| Atenolol | Atenolol | 46 | 14 |
| Mounjaro | Tirzepatide | 46 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 46 | 24 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 44 | 15 |
| Mirtazapine | Mirtazapine | 42 | 13 |
| Alendronate Sodium | Alendronate Sodium | 41 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 41 | 15 |
| Cephalexin | Cephalexin | 40 | 32 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 39 | 12 |
| Buspirone Hcl | Buspirone Hcl | 37 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 36 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 36 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 34 | 14 |
| Glipizide | Glipizide | 33 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 33 | 12 |
| Clonidine Hcl | Clonidine Hcl | 32 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 32 | suppressed |
| Valsartan | Valsartan | 32 | 11 |
| Amoxicillin | Amoxicillin | 29 | 22 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 27 | 17 |
| Valacyclovir | Valacyclovir Hcl | 27 | suppressed |
| Fluconazole | Fluconazole | 26 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 26 | 17 |
| Farxiga | Dapagliflozin Propanediol | 25 | suppressed |
| Hydrocortisone | Hydrocortisone | 25 | 12 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 24 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 23 | 14 |
| Benazepril Hcl | Benazepril Hcl | 22 | suppressed |
| Verapamil Er | Verapamil Hcl | 22 | suppressed |
| Januvia | Sitagliptin Phosphate | 21 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 21 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 21 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 20 | suppressed |
| Mupirocin | Mupirocin | 20 | 11 |
| Prednisone | Prednisone | 20 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 20 | 18 |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 19 | suppressed |
| Famotidine | Famotidine | 19 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 19 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 19 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 18 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 18 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 18 | suppressed |
| Torsemide | Torsemide | 18 | suppressed |
| Jardiance | Empagliflozin | 17 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 17 | suppressed |
| Telmisartan | Telmisartan | 17 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 17 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 16 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 16 | suppressed |
| Ketoconazole | Ketoconazole | 16 | suppressed |
| Topiramate | Topiramate | 16 | suppressed |
| Xarelto | Rivaroxaban | 16 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 15 | suppressed |
| Celecoxib | Celecoxib | 15 | suppressed |
| Chlorthalidone | Chlorthalidone | 15 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 15 | suppressed |
| Lansoprazole | Lansoprazole | 15 | suppressed |
| Lovastatin | Lovastatin | 15 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 14 | suppressed |
| Nystatin | Nystatin | 14 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 14 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 14 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Colchicine | Colchicine | 13 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 13 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 12 | suppressed |
| Ibu | Ibuprofen | 12 | suppressed |
| Verapamil Sr | Verapamil Hcl | 12 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 11 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 11 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 11 | suppressed |
| Levetiracetam | Levetiracetam | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
| Spironolactone | Spironolactone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $441.22 · 21 records | Novo Nordisk Inc | Cologuard Collection Kit, GEMTESA, JARDIANCE, Kerendia, MOUNJARO, NEXLETOL, Ozempic, Prospera, REPATHA, Rybelsus, Wegovy, ZEPBOUND | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error